Abstract: Accordingly to the method of the preparing of the tumor vaccine with the use of endothelial cells, live endothelial cells are treated with a protease at mild (non-deadly for cells) conditions, the splitted surface antigens are collected, the treatment of live endothelial cells is repeated after intervals which are necessary for the recovery of the surface antigens by the cells, surface antigens are accumulated until their necessary quantity is reached, the quality of the vaccine is controlled thereafter. The technical result obtained with the use of this invention consists in the enhancement of the efficiency of oncological disease treatment due to the damage of the tumor vessels caused by overcoming of the immune tolerance of organism to the endothelial cells (EC) of tumor vessels. Here one means the overcoming of immune tolerance namely to activated EC, which allows to damage mainly to the tumor vessels by the immune system.

Abstract: The group of inventions relates to medical engineering, in particular to the immunotherapy of cancer patients. The inventive tumor vaccine based on surface tumor antigens comprises a mixture of surface tumor antigens. The method for producing a tumor vaccine consists in cultivating tumor cells and in separating surface tumor antigens. The primary culture of living tumor cells, which is pre-washed of a growth medium, is exposed to a proteases action vital for cells and the thus released surface tumor antigens are separated. The primary culture of living tumor cells is repeatedly treated by proteases at intervals necessary for recovering the surface tumor antigens by means of cells. The surface tumor antigens are accumulated until a dose thereof, required for vaccination, is obtained, the composition of the thus obtained surface tumor antigens is tested. Trypsin can be used as protease. The method for carrying out antitumor immunotherapy consists in administrating the tumor vaccine in a patient body.

Abstract: Accordingly to the method of the preparing of the tumor vaccine with the use of endothelial cells, live endothelial cells are treated with a protease at mild (non-deadly for cells) conditions, the splitted surface antigens are collected, the treatment of live endothelial cells is repeated after intervals which are necessary for the recovery of the surface antigens by the cells, surface antigens are accumulated until their necessary quantity is reached, the quality of the vaccine is controlled thereafter. The technical result obtained with the use of this invention consists in the enhancement of the efficiency of oncological disease treatment due to the damage of the tumor vessels caused by overcoming of the immune tolerance of organism to the endothelial cells (EC) of tumor vessels. Here one means the overcoming of immune tolerance namely to activated EC, which allows to damage mainly to the tumor vessels by the immune system.